Prospective prevalence of pathologic gambling and medication association in Parkinson disease
- 13 June 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 66 (11) , 1750-1752
- https://doi.org/10.1212/01.wnl.0000218206.20920.4d
Abstract
The authors prospectively screened 297 patients with Parkinson disease (PD), who attended a tertiary clinic, using a modified South Oaks Gambling Scale. Lifetime prevalence of pathologic gambling (PG) was 3.4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist.Keywords
This publication has 9 references indexed in Scilit:
- Pathological Gambling Caused by Drugs Used to Treat Parkinson DiseaseArchives of Neurology, 2005
- Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's diseasePublished by Elsevier ,2005
- Pathological gambling is linked to reduced activation of the mesolimbic reward systemNature Neuroscience, 2005
- Pathological gambling: a comprehensive review of biobehavioral findingsNeuroscience & Biobehavioral Reviews, 2004
- Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatumJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2003
- Discrete Coding of Reward Probability and Uncertainty by Dopamine NeuronsScience, 2003
- The psychology and neurobiology of addiction: an incentive–sensitization viewAddiction, 2000
- The psychology and neurobiology of addiction: an incentive–sensitization viewAddiction, 2000
- The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblersAmerican Journal of Psychiatry, 1987